• 21 Apr 22

IQ-AI subsidiary Imaging Biometrics shares latest progress on Phase I brain cancer study

IQ-AI subsidiary Imaging Biometrics shares latest progress on Phase I brain cancer study

Imaging Biometrics Limited | IQAI | 0.7 0 0%

    • 82 views

 

IQ-AI subsidiary Imaging Biometrics CEO Michael Schmainda shares the latest progress on the group has made on its Phase I brain cancer clinical trial it has sponsored at the Medical College of Wisconsin. Schmainda says the study uses the group's imaging platform which is being used to asses patient's responses, and the group is now enrolling subjects.

Enjoying this article?

Get a £25 credit by sharing with your friends and colleagues via our Refer a Friend page. Each new subscriber gets a 10% discount and you get a free month off your bill every time.


Don't worry, if you're a Lite-Access/Free user we save all your credits for the day you decide to fully subscribe.


 

IQ-AI adds key board member as its Imaging Biometrics subsidiary expands GE partnership

Companies: Imaging Biometrics Limited

FDA StoneChecker clearance a 'validation and tremendous leap forward' for IQ-AI

Companies: Imaging Biometrics Limited

Imaging Biometrics Shares Promising Phase 1 Clinical Trial Results and Plans for Phase 2

Companies: Imaging Biometrics Limited

IQ-AI's David Smith explains proposed Stonechecker sale and 2020 vision

Companies: Imaging Biometrics Limited

IQ-AI advances glioblastoma clinical trial, eyes phase two in 2025

Companies: Imaging Biometrics Limited

More from Imaging Biometrics on the AI deal

Companies: Imaging Biometrics Limited

© Research Tree 2025

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top